Post by
megatron9191 on Oct 24, 2023 10:31am
Question
If Baxter does end up buying out the company when it reaches 90 patients, is there a possibility that shareholders are now awarded Baxter stock (which is valued at around $30)? How does the pay out work to the stakeholders?
Comment by
oilandgasman on Oct 24, 2023 10:42am
Nice chart.. 87.00 bucks in Jan 2022 Baxter stock has been in free fall mode for the past two years.
Comment by
Accountprince on Oct 24, 2023 4:27pm
If Baxter is trading at $30 then yes 1 Baxter shares for 10 Spectral shares. But Baxter's share price is in USD. So at an exchange rate of 1.35 the Spectral shares should trade at $4.05 a share (US$3.00 at 1.35).
Comment by
MMABStrader on Oct 24, 2023 4:46pm
I'm in the U.S. and I buy Spectral shares on the OTC. In my Baxter buy out example I was thinking of U.S. dollars for both sides of the transaction. I was assuming a buyout of Spectral at around $1.3 billion Canadian.
Comment by
Revten on Oct 25, 2023 11:34am
Very True MM. Potential will Also Be "Exceeding Expectations" IMHO And also a great question regarding the OTC Trading & Exposure etc... Thanks! Rev
Comment by
MMABStrader on Oct 25, 2023 11:57am
I picked the $3 U.S. buyout price to make it simple to explain what would happen in a Baxter buyout. Personally, I believe the ultimate buyout price will be between $3 and $5 U.S. It is easy to buy Spectral shares on the OTC as long as you are willing to buy shares at the ask price. In my Ameritrade account I can buy any quantity of EDTXF for a $3.95 commission.
Comment by
mercedesman on Oct 25, 2023 10:04pm
Thx Med...trader I was curious how much news flow on Spectral makes it there and the likelihood that an average investor might stumble upon it. It's a difficult stock to do your DD on , not to mention the mercurial nature of Sepsis itself and the difficulty in pinning down a solution particularly using a traditional 28-day mortality RCT to do so. MM